Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

New pharmaceutical products drive 11% volume growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
1Q Revenues: $5.7 billion (+9%)
1Q Earnings: $1.2 billion (loss of $110.8 million 1Q17)  
Comments: New pharmaceutical products, including Trulicity, Cyramza, Basaglar, Jardiance, Taltz, Lartruvo, Olumiant, and Verzenio, represented 25% of total revenue and drove 11% volume growth. These products help offset declines in established brands including Cialis, down 7% to $495.4 million, Forteo, down 10% to $313.2 million, Cymbalta and Erbitux, both down 3% to $169.6 million and $149.6 million, respectively. Trulicity sales were up 82% to $678.3 million in the quarter. Cyramza sales were $183.6 million, up 7%. Basaglar sales were up 261% to $166 million. Jardiance sales were $151 million, up 104%. Taltz sales were $146.5 million, up 52%. Lartruvo sales were up 535 to 64.4 million. Newer products Olumiant and Verzenio sales were $32.2 million and $29.7 million, respectively. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters